AR090647A2 - Adenovirus quimericos para uso en el tratamiento del cancer - Google Patents

Adenovirus quimericos para uso en el tratamiento del cancer

Info

Publication number
AR090647A2
AR090647A2 ARP130101163A ARP130101163A AR090647A2 AR 090647 A2 AR090647 A2 AR 090647A2 AR P130101163 A ARP130101163 A AR P130101163A AR P130101163 A ARP130101163 A AR P130101163A AR 090647 A2 AR090647 A2 AR 090647A2
Authority
AR
Argentina
Prior art keywords
adenovirus
chemicals
cancer
treatment
therapeutic index
Prior art date
Application number
ARP130101163A
Other languages
English (en)
Inventor
Harden Paul
Kuhn Irene
Hermiston Terry
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of AR090647A2 publication Critical patent/AR090647A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Adenovirus oncolíticos con aplicaciones terapéuticas. Se proveen adenovirus quiméricos recombinantes y métodos para producirlos. Los adenovirus quiméricos de la solicitud comprenden secuencias de ácido nucleico derivadas de los serotipos adenovirales clasificados en los subgrupos B a F y presentan un índice terapéutico diferente. Reivindicación 1: Un adenovirus oncolítico competente para su replicación del serotipo 11, caracterizado porque la región de la unidad de transcripción E3 y/o el gen E4orf4 contiene una deleción y donde el adenovirus presenta un índice terapéutico mejorado.
ARP130101163A 2004-05-26 2013-04-11 Adenovirus quimericos para uso en el tratamiento del cancer AR090647A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
AR090647A2 true AR090647A2 (es) 2014-11-26

Family

ID=35355425

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102135A AR049188A1 (es) 2004-05-26 2005-05-24 Adenovirus quimericos para uso en el tratamiento del cancer
ARP130101163A AR090647A2 (es) 2004-05-26 2013-04-11 Adenovirus quimericos para uso en el tratamiento del cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050102135A AR049188A1 (es) 2004-05-26 2005-05-24 Adenovirus quimericos para uso en el tratamiento del cancer

Country Status (33)

Country Link
US (6) US7510868B2 (es)
EP (1) EP1749098B1 (es)
JP (1) JP4787936B2 (es)
KR (1) KR101169109B1 (es)
CN (3) CN1997746B (es)
AR (2) AR049188A1 (es)
AT (1) ATE491799T1 (es)
AU (1) AU2005250396B2 (es)
BR (2) BRPI0510475B8 (es)
CA (2) CA2836987C (es)
CR (1) CR8794A (es)
DE (1) DE602005025340D1 (es)
DK (1) DK1749098T3 (es)
EC (1) ECSP067088A (es)
ES (1) ES2358204T3 (es)
GT (1) GT200500129A (es)
HK (3) HK1109421A1 (es)
HR (1) HRP20110179T1 (es)
IL (2) IL179098A (es)
MX (1) MXPA06013570A (es)
MY (1) MY140829A (es)
NO (1) NO340708B1 (es)
NZ (1) NZ551443A (es)
PA (1) PA8634201A1 (es)
PE (1) PE20060277A1 (es)
PL (1) PL1749098T3 (es)
PT (1) PT1749098E (es)
RU (1) RU2448157C2 (es)
TW (1) TWI366603B (es)
UA (1) UA89957C2 (es)
UY (1) UY28926A1 (es)
WO (1) WO2005118825A2 (es)
ZA (1) ZA200610763B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551443A (en) * 2004-05-26 2010-01-29 Schering Ag Chimeric adenoviruses for use in cancer treatment
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
AU2013231423B2 (en) * 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN104334188B (zh) * 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
WO2014131898A1 (en) * 2013-02-28 2014-09-04 Psioxus Therapuetics Limited A process for the production of adenovirus
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
CN112516179A (zh) 2013-06-14 2021-03-19 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
LT3021859T (lt) * 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
US20170313990A1 (en) 2014-08-27 2017-11-02 Psioxus Therapeutics Limited A process for the production of adenovirus
EP3391892A1 (en) * 2015-04-30 2018-10-24 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
JP7064437B2 (ja) 2015-12-17 2022-05-10 サイオクサス セラピューティクス リミテッド 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
US11273170B2 (en) * 2016-07-25 2022-03-15 Ascend Biopharmaceuticals Ltd Methods of treating cancer
EP3503918B1 (en) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
BR112019024918A2 (pt) 2017-06-01 2020-06-23 Psioxus Therapeutics Limited Vírus oncolítico e método
EP3679128A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. Method of targeting exosomes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
KR20210093303A (ko) 2018-11-21 2021-07-27 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 아데노바이러스 및 아데노바이러스의 사용 방법
JP7381604B2 (ja) 2019-04-29 2023-11-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 癌を治療するための多価ｐｄ－ｌ１結合化合物
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK0667912T3 (da) 1993-07-13 2008-11-10 Centelion Defekte adenovirusvektorer og anvendelse heraf i genterapi
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) * 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
WO2000070071A1 (en) * 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
EP1301612A2 (en) 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) * 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
NZ551443A (en) 2004-05-26 2010-01-29 Schering Ag Chimeric adenoviruses for use in cancer treatment
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof

Also Published As

Publication number Publication date
US20120231524A1 (en) 2012-09-13
IL226820A (en) 2017-07-31
UA89957C2 (ru) 2010-03-25
ZA200610763B (en) 2009-06-24
IL179098A (en) 2015-09-24
BR122013008865B8 (pt) 2021-05-25
NO20066002L (no) 2006-12-22
US20130209409A1 (en) 2013-08-15
MXPA06013570A (es) 2007-02-08
US20130230902A2 (en) 2013-09-05
ES2358204T3 (es) 2011-05-06
JP4787936B2 (ja) 2011-10-05
JP2008500051A (ja) 2008-01-10
US20150037874A1 (en) 2015-02-05
CA2567094C (en) 2014-11-25
MY140829A (en) 2010-01-29
GT200500129A (es) 2006-03-23
HK1179655A1 (en) 2013-10-04
UY28926A1 (es) 2006-01-31
BRPI0510475B8 (pt) 2021-05-25
ECSP067088A (es) 2007-01-26
US7510868B2 (en) 2009-03-31
AU2005250396B2 (en) 2010-11-11
BR122013008865B1 (pt) 2020-11-24
WO2005118825A3 (en) 2006-11-23
PT1749098E (pt) 2011-02-02
US20090227000A1 (en) 2009-09-10
US20050265973A1 (en) 2005-12-01
TW200611974A (en) 2006-04-16
US8765463B2 (en) 2014-07-01
HK1109421A1 (en) 2008-06-06
BRPI0510475A (pt) 2007-11-06
CN102816742A (zh) 2012-12-12
BRPI0510475B1 (pt) 2020-09-29
CN104263703A (zh) 2015-01-07
CN102816742B (zh) 2014-04-09
CR8794A (es) 2007-08-28
US8158599B2 (en) 2012-04-17
KR101169109B1 (ko) 2012-07-26
CN1997746A (zh) 2007-07-11
RU2448157C2 (ru) 2012-04-20
HK1205529A1 (en) 2015-12-18
CN1997746B (zh) 2012-09-26
CA2836987A1 (en) 2005-12-15
US9034344B2 (en) 2015-05-19
PA8634201A1 (es) 2006-11-09
TWI366603B (en) 2012-06-21
RU2006145071A (ru) 2008-07-10
US9115337B2 (en) 2015-08-25
EP1749098A2 (en) 2007-02-07
CN104263703B9 (zh) 2019-12-17
US9234185B2 (en) 2016-01-12
CN104263703B (zh) 2018-01-09
DE602005025340D1 (de) 2011-01-27
HRP20110179T1 (hr) 2011-04-30
US20130217095A1 (en) 2013-08-22
KR20070020302A (ko) 2007-02-20
NO340708B1 (no) 2017-06-06
PE20060277A1 (es) 2006-05-25
ATE491799T1 (de) 2011-01-15
WO2005118825A2 (en) 2005-12-15
DK1749098T3 (da) 2011-04-04
AR049188A1 (es) 2006-07-05
CA2836987C (en) 2016-07-05
CA2567094A1 (en) 2005-12-15
IL226820A0 (en) 2013-07-31
IL179098A0 (en) 2007-03-08
EP1749098B1 (en) 2010-12-15
NZ551443A (en) 2010-01-29
AU2005250396A1 (en) 2005-12-15
PL1749098T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
AR090647A2 (es) Adenovirus quimericos para uso en el tratamiento del cancer
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
CY1122385T1 (el) Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β
ZA201908445B (en) Recombinant adenoviruses carrying transgenes
MY175614A (en) Oncolytic adenoviruses armed with heterologous genes
WO2005107474A3 (en) Oncolytic adenovirus armed with therapeutic genes
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
NZ594355A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BRPI0418805B8 (pt) construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos
BRPI0407822A (pt) polinucleotìdeos e polipeptìdeos nas plantas
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
Fan et al. Targeting gene‐virotherapy for prostate cancer by dd3‐driven oncolytic virus‐harboring interleukin‐24 gene
Jin et al. Latent infection of human cytomegalovirus is associated with the development of gastric cancer
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
WO2018020323A3 (en) Materials and methods for treatment of fatty acid disorders
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
Yang et al. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus
CA3138834A1 (en) Oncolytic adenovirus and checkpoint inhibitor combination therapy
Kaliberov et al. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
BR112022008726A2 (pt) Vetor adenovírus recombinante com replicação viral melhorada, tipo celular específico e método de tratamento de uma malignidade
MY185846A (en) Oncolytic adenovirus encoding a b7 protein
RU2021109614A (ru) N-бензоилгидразоны камфоры, используемые в качестве ингибиторов репликации ортопоксвирусов

Legal Events

Date Code Title Description
FG Grant, registration